LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways

导出原文传递

翻译打印收藏纠错

作者： Chung, Seung Woo ^[1] ; Bae, Sang Mun ^[2] ; Lee, Myungjin ^[3] ; Al-Hilal, Taslim A. ^[4] ; Lee, Chang Kyung ; Kim, Jeong Kon ; Kim, In-San ; Kim, Sang Yoon ; Byun, Youngro

作者单位： Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea ^[1] Korea Basic Sci Inst, Div Magnet Resonance, Cheongwon 363883, Chungbuk, South Korea ^[2] Kyungpook Natl Univ, Sch Med, Dept Biochem & Cell Biol, Taegu 700422, South Korea ^[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Otolaryngol, Seoul 138736, South Korea ^[4]

关键词 Heparin Angiogenesis VEGF FGF2 PDGF-B

发布时间 2020-04-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Biomaterials

2015年37卷

271-278页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways

Biomaterials

相似文献

Biomaterials

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways

Biomaterials

相似文献

Biomaterials

相关期刊

检索历史清除